Jihua Chen on mitigating target interference in bridging immunogenicity assays

To give us an author’s perspective, Jihua Chen of Regeneron Pharmaceuticals (NY, USA) answers some of our questions probing his latest research publication and his current research focus. Jihua discusses the impact of the paper published in Bioanalysis and also outlines some of the major challenges faced by scientists hoping to develop reliable and robust bridging anti-drug antibody (ADA) assays. Dr Jihua Chen is a Senior Staff Scientist in the Assay Development Group at Regeneron Pharmaceuticals Inc. He supervises scientists in the development and validation of immunoassays (PK, ADA, neutralizing antibody (NAb) and biomarker) used in bioanalyses for both nonclinical...

To view this content, please register now for access

It's completely free